PMOS Meaning: What Polyendocrine Metabolic Ovarian Syndrome Actually Says

The name, one word at a time

The rename was published in The Lancet in 2026 after a multistep consensus process run across 56 academic, clinical and patient organisations. Every word in it was argued over, and each one is doing a job.

Part of the name	What it points at	Why it is there
Poly-	Many — as in many hormone systems	The same prefix as before, pointing somewhere accurate this time
-endocrine	The hormone-producing glands: ovaries, pituitary, adrenal, pancreas	“Endocrine” drew the highest support of any candidate word in the global surveys
Metabolic	Insulin resistance, blood glucose, lipids, liver fat	These features are common and were routinely missed under the old name
Ovarian	The ovaries — irregular or absent ovulation, androgen output	Ovarian dysfunction is still a defining feature, so it stays
Syndrome	A cluster of features that travel together	Diagnosis is still a pattern, not one number on one blood test

Read as a sentence, PMOS says: several hormone systems are involved, metabolism is part of it, and the ovaries are where it shows up. That is a fair description of the condition. “Polycystic ovary syndrome” was not.

“Polyendocrine” is the word carrying the most new information. The consensus paper describes the pathophysiology as multisystem, and that is what the glands list looks like in practice: the ovaries producing androgens, the pituitary driving them with luteinising hormone, the adrenal glands adding their own androgen output, and the pancreas releasing more insulin than it should have to. Four glands, one pattern. The old name named one of them.

Why “polycystic” had to go

The cysts were never cysts.

What shows up on an ovarian ultrasound in this condition is a high count of small immature follicles — normal ovarian structures that started developing and stalled. They are not pathological cysts, they do not need draining, and they are not dangerous in themselves.

The 2023 international guideline sets the threshold for polycystic ovarian morphology at 20 or more follicles in either ovary, or an ovarian volume of 10 mL or more, using a transvaginal probe of at least 8 MHz. That is a follicle count, not a cyst count.

The same guideline allows anti-Müllerian hormone as an alternative to ultrasound for defining polycystic ovarian morphology in adults. A 2024 systematic review of 82 studies found AMH detected PCOS in adults with a pooled sensitivity of 0.79 and specificity of 0.87 — good enough to stand in for the scan in adults, not good enough in adolescents, where sensitivity fell to 0.66. AMH alone still cannot diagnose the condition on its own.

So the defining ovarian feature is a hormone level or a follicle count. Neither is a cyst. The word in the old name described something that does not exist.

The part of the meaning most people miss

Here is the detail that makes “polycystic” more than a cosmetic error: you can be diagnosed without polycystic ovaries at all.

Diagnosis uses two of three features — irregular ovulation, clinical or biochemical excess androgens, and polycystic ovarian morphology. Two out of three. One recognised phenotype has irregular cycles and high androgens with entirely normal-looking ovaries on a scan.

If that is you, the old name described a finding you never had, which is exactly the situation that sends someone away from an appointment told their scan was “clear”. The four phenotype patterns differ in which features are present, and the new name is the first one that is accurate for all of them.

What actually changed, and what did not

Item	Status after the 2026 consensus
The name	Changed. Polyendocrine metabolic ovarian syndrome (PMOS)
The term “PCOS”	Still in circulation. The consensus chose evolution over transformation and built in a transition period
Diagnostic criteria	Unchanged. The 2023 guideline criteria still apply
Your existing diagnosis	Unchanged. Nobody is being re-diagnosed or re-tested
Treatment and medication	Unchanged. No prescription changes because of a word
Coding and health records	Alignment with disease classification systems is under way, not finished
The biology	Unchanged. The condition is exactly what it was in 2025

That last row is worth sitting with for a second at 11pm. A name change can read as though something has been discovered or reclassified. Nothing has. The condition, the mechanism and the evidence base are identical to what they were the week before the paper published. A fuller comparison lives in PCOS vs PMOS.

How the name was chosen

Not by a committee picking a nicer word.

The process ran iterative global surveys with 14,360 responses from people with the condition and health professionals across every world region, then modified Delphi rounds, then nominal group workshops, then marketing and implementation analysis.

The direction was already clear before that. A longitudinal survey published in 2025 found that in its 2023 round, 85.6% of patients and 76.1% of health professionals agreed the name should change. Asked which words belonged in a replacement, “endocrine” and “metabolic” drew the strongest support — 86.2% of patients and 79.6% of health professionals.

The same survey found the knowledge gap the name had been feeding: 20% or more of patients and clinicians did not recognise the links between this condition and fatty liver disease, pregnancy complications, cardiovascular risk factors, or endometrial cancer. A name that says only “ovary” makes those associations easy to not go looking for. The consensus group argued the wider case for that logic in a 2026 paper on medical naming. If you want the full reasoning, why PCOS was renamed covers it properly.

How common is it, under either name

The consensus paper describes PMOS as affecting one in eight women. A 2024 meta-analysis of 35 studies covering 12.3 million people put global prevalence at 9.2%, rising to 11.5% when Rotterdam criteria were used and falling to 5.5% under the narrower NIH criteria.

The spread is the point: prevalence depends on which criteria you apply, not on which name you use.

How to say it, and the other PMOS

Say the full name as four words — polyendocrine metabolic ovarian syndrome — then use the initials. The acronym is read letter by letter: P-M-O-S.

If your search results look nothing like a health condition, this is why. PMOS has been an abbreviation in electronics for decades, for p-channel metal-oxide-semiconductor transistors. Adding “syndrome” or “PCOS” to the search separates the two.

Which word should you use

Both are correct right now. In practice:

• Talking to a clinician: lead with whichever term is on your records, usually PCOS, and add PMOS if it helps.
• Searching for information: search both. Most of the last twenty years of research is indexed under PCOS, and it does not stop being valid.
• Explaining it to someone: PMOS is easier. “It’s a hormone and metabolic condition that affects the ovaries” is a sentence people understand. “Polycystic ovaries” invites a question about cysts you then have to correct.

Your next step

Write one line at the top of the notes you take into your next appointment: “PCOS / PMOS — I want to know which criteria I met and whether my insulin and lipids have been checked.”

That single question turns the new name into something useful, because “metabolic” is the word that was missing and the labs that go with it are the ones most often skipped. There is a script for that conversation in telling your doctor about PMOS, and the rest of the diagnosis section covers what each criterion actually measures.